J&J/Janssen win FDA nod for Simponi in ulcerative colitis
This article was originally published in Scrip
Executive Summary
Johnson & Johnson unit Janssen Biotech gained the US FDA's approval to market Simponi (golimumab) as a treatment for with moderate to severe ulcerative colitis (UC) resistant to prior treatment or requires continuous steroid therapy.